ABN AMRO Bank N.V. Acquires 220,969 Shares of Edwards Lifesciences Corporation $EW

ABN AMRO Bank N.V. increased its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 124.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 398,425 shares of the medical research company’s stock after buying an additional 220,969 shares during the period. ABN AMRO Bank N.V.’s holdings in Edwards Lifesciences were worth $32,255,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in EW. State Street Corp grew its position in Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares in the last quarter. Wellington Management Group LLP raised its holdings in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after acquiring an additional 989,533 shares in the last quarter. Norges Bank bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $803,686,000. Morgan Stanley lifted its position in shares of Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company’s stock valued at $623,544,000 after acquiring an additional 804,942 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock worth $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the transaction, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 81,038 shares of company stock valued at $6,683,255. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Up 1.2%

Shares of NYSE:EW opened at $90.81 on Friday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $92.46. The company has a market capitalization of $52.29 billion, a PE ratio of 48.30, a price-to-earnings-growth ratio of 2.28 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The company has a fifty day moving average of $84.41 and a 200-day moving average of $83.26.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. TD Cowen restated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Truist Financial set a $90.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Evercore reissued an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Monday, April 13th. Finally, Barclays restated an “overweight” rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.